Adeza (NASDAQ:ADZA) today announced financial results for the three
and nine months ended September 30, 2005. Adeza reported record
quarterly product sales of $11.4 million for the third quarter of
2005, an increase of 30% from product sales of $8.8 million for the
third quarter of 2004. This increase is primarily attributable to
higher sales volume of FullTerm(R), The Fetal Fibronectin Test. Net
income for the third quarter of 2005 was $2.2 million, marking the
company's 13th consecutive profitable quarter. This compares with
net income of $5.2 million for the third quarter of 2004, which
included a one-time decrease in royalty expenses of $3.7 million.
Diluted earnings per share for the third quarter of 2005 was $0.12
based on 17.9 million shares outstanding, up from the $0.10
reported in the second quarter of 2005 and compared with diluted
earnings per share of $0.39 based on 13.5 million shares
outstanding for the third quarter of 2004, which included the
one-time decrease in royalty expense. The change in share count is
primarily the result of the completion of the company's initial
public offering of 4.3 million common shares in December 2004. For
the three months ended September 30, 2005, selling and marketing
expenses were $4.6 million, up from $4.2 million for the comparable
period in 2004, due mainly to expansion of the direct sales force
and marketing programs. General and administrative expenses for the
quarter increased to $2.0 million from $1.1 million in the
prior-year third quarter, due primarily to costs associated with
operating as a public company. Research and development expenses
were $1.6 million for the third quarter of 2005, compared with $0.6
million last year, due primarily to costs related to expanded
product development efforts and clinical studies. Product sales for
the first nine months of 2005 totaled $31.7 million, an increase of
30% from $24.4 million for the first nine months of 2004. For the
nine months ended September 30, 2005, Adeza reported net income of
$5.4 million, or $0.31 per diluted share based on 17.8 million
shares outstanding, compared with net income of $7.3 million, or
$0.54 per diluted share based on 13.4 million shares outstanding.
As of September 30, 2005, Adeza had cash and cash equivalents of
$86.8 million, stockholders' equity of $89.1 million and working
capital of $88.6 million. "We are reporting another quarter of
solid financial performance with continued profitability on record
product sales, driven by additional market penetration of our
FullTerm, The Fetal Fibronectin Test," said Emory V. Anderson,
president and chief executive officer of Adeza. "We continue to
execute on our strategy of leveraging our existing sales and
marketing infrastructure to increase utilization of our test in the
current customer base and to add new customers in our core
'signs-and-symptoms' market, while implementing marketing programs
that support testing women who are at 'high risk' for preterm
birth." Conference Call Adeza's management will host an
investment-community conference call today at 4:30 p.m. Eastern
Time (1:30 p.m. Pacific Time) to discuss these results and answer
questions. Individuals interested in participating in the
conference call may do so by dialing (888) 463-4383 for domestic
callers, or (706) 634-5615 for international callers. A telephone
replay will be available for 48 hours following the conclusion of
the call by dialing (800) 642-1687 for domestic callers, or (706)
645-9291 for international callers, and entering reservation code
1889378. The live call will also be available via the Internet via
the Investors section of the company's Web site at www.adeza.com. A
webcast replay of the call will be made available following the
conclusion of the call. About Adeza Adeza designs, manufactures and
markets innovative products for women's health. Adeza's initial
focus is on reproductive healthcare, using its proprietary
technologies to predict preterm birth and assess infertility.
Adeza's principal product is a patented diagnostic test, FullTerm,
The Fetal Fibronectin Test, which utilizes a single-use, disposable
cassette and is analyzed on Adeza's patented TLiIQ(R) System. This
product is approved by the U.S. Food and Drug Administration (FDA)
for use in assessing the risk of preterm birth. Adeza also markets
and sells the E-tegrity(R) Test, an infertility-related test to
assess receptivity of the uterus to embryo implantation in women
with unexplained infertility. Adeza cautions you that statements
included in this press release that are not a description of
historical facts may be forward-looking statements, including, for
example, statements relating to Adeza's sales and marketing
strategy. The inclusion of forward-looking statements should not be
regarded as a representation by Adeza that any of its plans will be
achieved. Actual results may differ materially from those set forth
in this release due to the risks and uncertainties inherent in
Adeza's business including, without limitation, risks and
uncertainties relating to the expansion of products, markets and
offerings and additional product indications. All forward-looking
statements are qualified in their entirety by this cautionary
statement and Adeza undertakes no obligation to revise or update
this news release to reflect events or circumstances after the date
hereof. -0- *T Adeza Condensed Statements of Operations (Unaudited)
(in thousands, except share and per share information) Three months
ended Nine months ended September 30, September 30,
----------------------- ----------------------- 2005 2004 2005 2004
----------- ----------- ----------- ----------- Product sales
$11,419 $8,767 $31,663 $24,405 Cost of product sales 1,703 (2,448)
4,559 895 ----------- ----------- ----------- ----------- Gross
profit 9,716 11,215 27,104 23,510 Operating costs and expenses:
Selling and marketing 4,566 4,153 14,078 11,638 General and
administrative 1,959 1,079 5,363 2,631 Research and development
1,634 559 3,711 1,755 ----------- ----------- -----------
----------- Total operating costs and expenses 8,159 5,791 23,152
16,024 ----------- ----------- ----------- ----------- Income from
operations 1,557 5,424 3,952 7,486 Interest income 729 48 1,802 104
----------- ----------- ----------- ----------- Income before
provision for income taxes 2,286 5,472 5,754 7,590 Provision for
income taxes 136 226 319 307 ----------- ----------- -----------
----------- Net income $2,150 $5,246 $5,435 $7,283 ===========
=========== =========== =========== Basic net income per share
$0.13 $28.77 $0.32 $39.97 =========== =========== ===========
=========== Diluted net income per share $0.12 $0.39 $0.31 $0.54
=========== =========== =========== =========== Shares used to
compute basic net income per share 16,990,858 182,344 16,802,712
182,222 =========== =========== =========== =========== Shares used
to compute diluted net income per share 17,931,154 13,454,649
17,797,756 13,383,760 =========== =========== ===========
=========== Adeza Condensed Balance Sheets (in thousands, except
share and per share information) September December 30, 31, 2005
2004 ----------- -------- (unaudited) Assets Current assets: Cash
and cash equivalents $86,849 $80,118 Accounts receivable, net 7,765
6,628 Inventories 739 667 Prepaid and other current assets 261 271
----------- -------- Total current assets 95,614 87,684 Property
and equipment, net 354 268 Intangible assets, net 140 176
----------- -------- Total assets $96,108 $88,128 ===========
======== Liabilities and stockholders' equity Current liabilities:
Accounts payable $2,491 $2,750 Accrued compensation 1,515 1,863
Accrued royalties 699 1,007 Other accrued liabilities 2,201 752
Deferred revenue 59 45 ----------- -------- Total current
liabilities 6,965 6,417 Commitments Stockholders' equity: Common
stock, $0.001 par value; 100,000,000 shares authorized; 17,117,167
and 16,461,390 shares issued and outstanding at September 30, 2005
and December 31, 2004, respectively 17 16 Additional paid-in
capital 131,022 129,695 Deferred compensation (2,563) (3,232)
Accumulated deficit (39,333) (44,768) ----------- -------- Total
stockholders' equity 89,143 81,711 ----------- -------- Total
liabilities and stockholders' equity $96,108 $88,128 ===========
======== *T
Adeza (NASDAQ:ADZA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Adeza (NASDAQ:ADZA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024